Scholar Rock Anticipates CHMP Opinion in 2027 Following ISEMBYLD FDA Approval
Scholar Rock (SRRK) has successfully launched ISEMBYLD in the United States following an expedited FDA approval that occurred ahead of its scheduled PDUFA date. The company is now focused on commercial execution and managing its regulatory pipeline, including anticipation of a CHMP opinion in the first half of 2027. To bolster its financial position, Scholar Rock is moving to monetize a Priority Review Voucher (PRV) valued at approximately $205 million. This liquidity event provides significant capital to support ongoing operations and the commercial rollout of its newly approved therapeutic.
Tickers: $SRRK
Topics: Biotechnology Earnings Call FDA Approval Product Launch
Read the full article at Seeking Alpha
Part of the story BioNTech Acquires Rare Pediatric Disease Priority Review Voucher from Scholar Rock for $205 Million (3 articles)